Bessemer Group
MAZE

Bessemer Group’s Maze Therapeutics MAZE Stock Holding History

Bessemer Group’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.4M Hold
481,790
– – 0.02% 312
2025
Q4 		$20M Hold
481,790
– – 0.03% 281
2025
Q3 		$12.5M Hold
481,790
– – 0.02% 298
2025
Q2 		$5.91M Hold
481,790
– – 0.01% 342
2025
Q1 		$5.3M Buy
+481,790
New +$5.8M 0.01% 346

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Bessemer Group's MAZE Position: Q1 2026 in Review

Bessemer Group held its Maze Therapeutics (MAZE) position steady in Q1 2026 at 481,790 shares worth $14.4M. The position accounts for 0.02% of the portfolio, ranked #312.

Bessemer Group first reported a position in MAZE in Q1 2025 and has held it in 5 quarters since. The position peaked at $20M in Q4 2025. 165 funds tracked by Wall St. Rank hold MAZE as of Q1 2026.

  • Bessemer Group held 481,790 shares of Maze Therapeutics worth $14.4M as of Q1 2026.
  • Bessemer Group left its Maze Therapeutics share count unchanged in Q1 2026.
  • Maze Therapeutics made up 0.02% of Bessemer Group's portfolio in Q1 2026, its #312 holding.
  • Bessemer Group first reported a position in Maze Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Bessemer Group's Maze Therapeutics position peaked at $20M in Q4 2025.
  • 165 funds tracked by Wall St. Rank held Maze Therapeutics as of Q1 2026.

Based on Bessemer Group's 13F filing for Q1 2026, filed 6 May 2026.